Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Yamamoto,Hirofumi; Oshiro,Ryota; Nishimura,Junichi; Uemura,Mamoru; Haraguchi,Naotsugu; Hata,Taishi; Takemasa,Ichiro; Mizushima,Tsunekazu; Sekimoto,Mitsugu; Doki,Yuichiro; Mori,Masaki

doi:10.3892/or.2013.2345

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Authors:
- Hirofumi Yamamoto
- Ryota Oshiro
- Junichi Nishimura
- Mamoru Uemura
- Naotsugu Haraguchi
- Taishi Hata
- Ichiro Takemasa
- Tsunekazu Mizushima
- Mitsugu Sekimoto
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, National Hospital Organization, Osaka National Hospital, Osaka, Japan
Published online on: March 13, 2013 https://doi.org/10.3892/or.2013.2345
Pages: 1751-1755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

View Figures

View References

1	de Bree E, Keus R, Melissas J, Tsiftsis D and van Coevorden F: Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 9:525–535. 2009.PubMed/NCBI
2	Berri RN, Baumann DP, Madewell JE, Lazar A and Pollock RE: Desmoid tumor: current multidisciplinary approaches. Ann Plast Surg. 67:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al: Desmoid tumors in familial adenomatous polyposis. Gut. 35:377–381. 1994. View Article : Google Scholar : PubMed/NCBI
4	Clark SK and Phillips RK: Desmoids in familial adenomatous polyposis. Br J Surg. 83:1494–1504. 1996. View Article : Google Scholar : PubMed/NCBI
5	Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC and McGannan E: Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 33:639–642. 1990. View Article : Google Scholar : PubMed/NCBI
6	Clark SK, Neale KF, Landgrebe JC and Phillips RK: Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 86:1185–1189. 1999. View Article : Google Scholar : PubMed/NCBI
7	Heiskanen I and Jarvinen HJ: Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis. 11:157–162. 1996. View Article : Google Scholar : PubMed/NCBI
8	Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, et al: Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 24:102–105. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lynch HT, Fitzgibbons R Jr, Chong S, Cavalieri J, Lynch J, Wallace F, et al: Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner’s syndrome. Dis Colon Rectum. 37:260–267. 1994.PubMed/NCBI
10	Patel SR, Evans HL and Benjamin RS: Combination chemotherapy in adult desmoid tumors. Cancer. 72:3244–3247. 1993. View Article : Google Scholar : PubMed/NCBI
11	Poritz LS, Blackstein M, Berk T, Gallinger S, McLeod RS and Cohen Z: Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum. 44:1268–1273. 2001. View Article : Google Scholar : PubMed/NCBI
12	Ezumi K, Yamamoto H, Takemasa I, Nomura M, Ikeda M, Sekimoto M and Monden M: Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Jpn J Clin Oncol. 38:222–226. 2008. View Article : Google Scholar
13	Gottlieb JA, Benjamin RS, Baker LH, O’Bryan RM, Sinkovics JG, Hoogstraten B, et al: Role of DTIC (NSC-45388) in the chemotherapy of sarcoma. Cancer Treat Rep. 60:199–203. 1976.PubMed/NCBI
14	Gottieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP Jr, Sinkovics JG, et al: Chemotherapy of sarcoma with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer. 30:1632–1638. 1972. View Article : Google Scholar : PubMed/NCBI
15	CTCAE v3.0 and v4.0 provided by the National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
16	Nakada I, Ubukata H, Goto Y, Watanabe Y, Sato S, Tabuchi T, et al: Prednisolone therapy for intra-abdominal desmoid tumors in a patient with familial adenomatous polyposis. J Gastroenterol. 32:255–259. 1997. View Article : Google Scholar : PubMed/NCBI
17	Bauernhofer T, Stoger H, Schmid M, Smola M, Gurtl-Lackner B, Hofler G, et al: Sequential treatment of recurrent mesenteric desmoid tumor. Cancer. 77:1061–1065. 1996. View Article : Google Scholar : PubMed/NCBI
18	Kono T, Tomita I, Chisato N, Matsuda M, Kakisaka A and Kasai S: Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanal pouch mesenteric desmoid tumor: report of case. Dis Colon Rectum. 47:246–249. 2004. View Article : Google Scholar : PubMed/NCBI
19	Weiss AJ, Horowiz S and Lackman RD: Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 22:193–195. 1999. View Article : Google Scholar : PubMed/NCBI
20	Okuno SH and Edmonson JH: Combination chemotherapy for desmoid tumors. Cancer. 97:134–135. 2003. View Article : Google Scholar
21	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
22	Hansmann A, Adolph C, Vogel T, Unger A and Moeslein G: High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 100:612–620. 2004. View Article : Google Scholar : PubMed/NCBI
23	Patel SR and Benjamin RS: Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol. 24:11–12. 2006. View Article : Google Scholar : PubMed/NCBI